Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Non-Cardiac Surgery with Incomplete Revascularization, Associated to Events

This study presented at the American Heart Association Scientific Sessions 2016 and simultaneously published in the Journal of the American College of Cardiology, showed incomplete revascularization is associated with an increased risk of adverse cardiac events, particularly infarction, in patients that must later receive non-cardiac surgery.

 

Patients with incomplete revascularization (defined as a ≥ 50% left main lesion or a ≥ 70% lesion in any major epicardial vessel) have a 19% higher risk of events at 30 days when facing non-cardiac surgery vs. patients with complete revascularization (p=0.05).

 

The difference was basically driven by a 37% increase in infarction risk (p=0.01). For each unrevascularized vessel, perioperative infarction risk increased 17% (p<0.001).

 

The study included 12,486 patients undergoing PCI and subsequent non-cardiac surgery. Of these patients, 35% arrived to the OR with incomplete revascularization.

 

Prior evidence is from the CARP study (Coronary Artery Revascularization Prophylaxis), which included 5,859 patients with prior revascularization surgery programed to receive non-cardiac surgery.

 

In the CARP study, revascularization did not change long term events rate, which led to minimizing revascularization prior to surgery. However, the CARP study was published ten years ago.

 

In this new study, researchers have found out a significant interaction with the time of non-cardiac surgery. Patients undergoing non cardiac surgery 6 weeks before PCI with incomplete revascularization had 84% more perioperatory risk compared to those with complete revascularization operated within the same timeframe.

 

Risk was no higher in those operated beyond 6 weeks after PCI.

 

One of the limitations to this study is that it was not possible to determine the type of post operatory MI. They could have been caused by either troponin elevation, plaque rupture or stent thrombosis.

 

Original Title: Incomplete revascularization is associated with an increased risk of major adverse cardiovascular events among patients undergoing non-cardiac surgery.

Presenter:  Armstrong EJ.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...